The effect of indomethacin treatment of patent ductus arteriosus (PDA) on blood pressure was studied in 24 preterm infants. PDA was diagnosed clinically and confirmed by echocardiography; the effect of treatment was monitored echocardiographically. Hourly intra-arterial recordings of systolic, diastolic, and mean blood pressure were averaged for the 48 hours before the first dose of indomethacin and for each of the three 24 hour periods after the first dose.
The conventional view of the effect of a patent ductus arteriosus (PDA) on systemic blood pressure has been that shunting in diastole causes a decrease in diastolic pressure and hence a widening of the pulse pressure.' This view has not stood up to close examination in preterm infants. In a cross sectional study we showed that haemodynamically significant PDA was associated with similar reductions in systolic and diastolic blood pressure and that as a result pulse pressure was not affected.2 In a cross sectional study it is difficult to control completely for confounding variables. For example, in our study there was a statistically insignificant trend to infants with PDA needing higher mean maximum ventilatory pressures. 2 Another method by which to examine the effect of PDA on blood pressure is to study the changes in blood pressure longitudinally around the time of PDA closure. Increases of similar degrees in systolic and diastolic blood pressure have been documented at the time of surgical ligation of the PDA.3-5 The effect of ductal closure induced by indomethacin on each of the parameters of blood pressure has not to our knowledge been documented. If changes consistently occurred, they might provide a further clinical pointer to the success of indomethacin treatment in an area where clinical signs can be unreliable. 6 The aims of this study were twofold. Firstly, to confirm our cross sectional findings with a study of the change in the parameters of blood pressure which occur around successful and unsuccessful medical closure of PDA; and, secondly, to see if changes in blood pressure could be used as a reliable clinical indicator of successful medical closure.
Subjects and methods
Twenty four preterm infants were studied before and during indomethacin treatment for a PDA. Their mean gestational age was 27 weeks (24-30 weeks) and the mean birth weight 913 g (519-1610 g). The infants were recruited during three six month periods, ending February 1989 and July 1991 at the John Radcliffe Maternity Hospital in Oxford, and ending July 1992 at the King George V Hospital in Sydney, Australia. Criteria for inclusion in the study were firstly that there was intra-arterial blood pressure monitoring for at least 24 hours before and 48 hours after the first dose of indomethacin, and secondly that there was echocardiographic confirmation of ductal patency before treatment and echocardiographic monitoring of the effect of that treatment.
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inufacturers'
All infants were mechanically ventilated at signal' was the time of treatment. In the successfully pressure was treated infants, the mean FiO2 and mean airmean blood way pressure decreased in the three days after s used in the the first dose of indomethacin, whereas they -e point for increased in those where treatment was not pressure was successful (table 2) . ethacin.
The hourly recordings of blood pressure concentra-were averaged for the 48 hours before the first oressure were dose of indomethacin and then for each of the )eriods as an three subsequent 24 hour periods. The mean )olicy on the of each parameter in the pretreatment 48 hours 102 and ven-was taken as the baseline for each infant and and trans-the change in blood pressure for each of !en with a closed or a restricting but patent duct; the mean increase was 5-3 and 4 mm Hg *18) 0-46 (0-18) respectively (p=055). By the third day, the average increase in mean blood pressure was (10) 104 mm Hg with a range of from 1 to 23 mm Hg. Of the 14 infants studied to day 3, all except one showed an increase in mean blood pressure of at least 4 mm Hg. This infant had a ventricular septal defect as well as a PDA. Two other infants were only studied for 48 hours; in one blood pressure monitoring was discontinued and the other died. The former had shown an increase in mean blood pressure of 7 mm Hg on day 2; the latter had fulminating respiratory failure and had an increase in mean blood pressure of only 1 mm Hg.
Changes in systolic and diastolic blood pressure were studied in 15 of the 16 infants; the other infant had a damped trace. Systolic and diastolic blood pressure also increased progressively by similar amounts after indomethacin treatment (fig 2) . The two parameters had shown a significant increase from day 1 onwards from their respective pretreatment values (p<005). There was a statistically insignificant trend to diastolic pressure increasing earlier than systolic; however, by day 3 the mean change in systolic blood pressure was 114 mm Hg and diastolic blood pressure was 10-6 mm Hg. As a result of this, there was no consistent change in pulse pressure with PDA closure (fig 3) . The average change in pulse pressure on day 3 was an insignificant increase of 1-0 mm Hg with a range from -9 to +9 mm Hg. Arterial catheter site had no significant influence on the change in pulse pressure. In the 12 infants with a postductal arterial catheter site the mean pulse pressure increased by 1-5 mm Hg between the pretreatment period and day 3 after treatment (24 to 25-5 mm Hg). In the three infants with a preductal catheter site, the mean pulse pressure decreased by 1 mm Hg over the same time period (23 to 22 mm Hg) (p=06).
INFANTS TREATED UNSUCCESSFULLY
In these eight infants there was no significant difference between the average mean blood pressure in the two 24 hour periods before the first dose. The average mean blood pressures for these periods were 32-7 and 32-6 mm Hg respectively (p=0-8). After the first dose of indomethacin there was no significant change in average mean blood pressure on any of the subsequent three days (fig 4) . On day 3 the average change on mean blood pressure was zero with a range from -3 to +3 mm Hg. Systolic and diastolic blood pressure and pulse pressure likewise showed no significant change over this three day period. Blood pressure was monitored in Sonnesson's study with a Dinamap oscillometric monitor, a method since shown to be not consistently accurate in preterm infants. 8 We are not aware that changes in systolic, mean, and diastolic blood pressure have been previously documented at the time of medical PDA closure. In this study we have shown that where medical treatment is successful, there is a gradual and significant increase in all the parameters of blood pressure over the three days after the first dose of indomethacin. Increases in systolic and diastolic blood pressure are similar and as a result pulse pressure is not consistently affected by PDA closure. This seems to confirm our cross sectional findings2 in preterm infants that the effect of a PDA on blood pressure is general, and that a change in pulse pressure cannot be seen as a reliable indicator of ductal patency or ductal closure.
Were there other factors which could explain the increases in blood pressure reported here?
The mean age at treatment in the successful group was 5 days and it has been reported that blood pressure increases over the first week of life in term and preterm infants.9 Although this may have contributed to the increase, the difference in average mean blood pressure in the two 24 hour periods before the first dose of indomethacin was not significant. As indomethacin has widespread vasoconstrictor activity'0 1 l and also causes disturbance of fluid and electrolyte balance,12 could these effects have increased blood pressure in isolation from the effect on the duct? Although this is again possible, the fact that the infants in whom the duct did not close showed no consistent change in blood pressure makes it unlikely.
Why should PDA closure increase blood pressure? Systemic blood pressure is a product of cardiac output and systemic vascular resistance. A PDA connects the relatively high resistance systemic circulation to the low resistance pulmonary circulation; a left to right shunt and a reduction in systemic vascular resistance results. The left ventricle responds by increasing cardiac output to cope with the volume load and to maintain systemic pressures.'3 The ductal shunt occurs throughout the cardiac cycle with maximum velocity and flow in systole,14 and as a result systolic and diastolic pressures will tend to decrease. The extent to which they decrease will depend on the size of the shunt and the ability of the left ventricle to compensate. '3 When the duct is closed, the peripheral vascular resistance increases immediately, cardiac output decreases,'5 and blood pressure increases. Clearly, echocardiography is the most accurate means of assessing the success of a course of indomethacin; however, many neonatal units do not have immediate access to echocardiographic skills and so rely on clinical criteria and physical signs. Fourteen of the 16 successfully treated infants studied here showed an increase in mean blood pressure of 4 mm Hg or more; none of the eight unsuccessfully treated infants showed an increase of more than 3 mm Hg. The two groups were not completely comparable in that the unsuccessful group was of lower gestational and higher postnatal age, documented risk factors for a lack of response to indomethacin.'6 It would seem, however, that an increase in arterial blood pressure is a useful additional clinical pointer to successful medical PDA closure.
In conclusion, this study has confirmed longitudinally that the PDA is one of the determinants of blood pressure in early preterm life. The effect on blood pressure is global and as a result arterial pulse pressure is not consistently affected by significant ductal shunting. Successful medical PDA closure is usually associated with a general increase in systemic blood pressure. 
